BD and Mitsubishi Gas Chemical have signed a letter of intent (LOI) to discuss a partnership agreement to explore new ways to advance biologic drug delivery
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Mitsubishi Gas Chemical Company, Inc. (MGC), a R&D-oriented chemical manufacturer based in Tokyo, Japan, today announced that they have entered into an agreement to investigate further development of OXYCAPT™ – an innovation from MGC that integrates the best of plastic and glass for plastic syringes. Together, the companies will look into applying the OXYCAPT™ technology to the next generation of prefillable syringes (PFS) for advanced biologic pharmaceuticals. BD has been working for decades to optimize the performance of PFS, which improves the delivery of drugs and vaccines. Today, BD is the world leader in supplying PFS to the biopharmaceutical industry – with more than 70 percent of the top 100 biopharmaceutical companies utilizing our devices. BD is proud to manufacture both glass and plastic PFS to meet the unique needs of drugs. “The biopharmaceutical industry continues to rely on PFS for the effective, reliable and consistent administration of medications,” said Bruno Baney, Vice President, R&D BD Medical – Pharmaceutical Systems. “As our customers continue to grow their drug pipelines, we are constantly exploring solutions to deliver newer compounds in robust, stable, and ready-to-administer formats. This agreement will further help us do so – as MGC’s experience in providing technical innovation in materials will serve as a strategic complement to our legacy of supporting the latest innovations in drug delivery for our customers.” MGC has developed the OXYCAPT™ multilayer structure applied on silicon free plastic syringe barrels to provide high breakage resistance, oxygen and vapor barrier, low protein adsorption, very low extractables, high UV barrier and pH stability. “Since launching OXYCAPT™, more and more pharmaceutical companies have been interested in applying it to their biologics or regenerative medicines such as gene/cell therapies”, said Ko Kedo, an executive officer of R&D division. “As we have looked for a strategic partner to enhance presence of OXYCAPT™ in the pharmaceutical industry, the partnership with BD will be an ideal solution for MGC. We believe this agreement will make it possible for customers to choose the best syringes for their drugs.”
https://www.mgc.co.jp/
